NextCure, Inc. (NXTC) Covered Calls
There are no covered calls available for NextCure, Inc..
Born To Sell's covered call screener gives you full search capabilities so you can find stocks and ETFs that make good covered call candidates.
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.
| Top 10 Open Interest For Nov 21 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | IBIT covered calls | 6. | INTC covered calls | 1. | GHRS covered calls | |
| 2. | KVUE covered calls | 7. | TLT covered calls | 2. | IREN covered calls | |
| 3. | NVDA covered calls | 8. | ASST covered calls | 3. | SRPT covered calls | |
| 4. | SLV covered calls | 9. | EEM covered calls | 4. | UPST covered calls | |
| 5. | GLD covered calls | 10. | HYG covered calls | 5. | HUT covered calls | |
Want more examples? NXT Covered Calls | NYF Covered Calls
